stoxline Quote Chart Rank Option Currency Glossary
  
BioVie Inc. (BIVI)
0.44  0.003 (0.59%)    05-30 16:00
Open: 0.4458
High: 0.4492
Volume: 342,668
  
Pre. Close: 0.4374
Low: 0.428
Market Cap: 27(M)
Technical analysis
2024-05-30 4:40:08 PM
Short term     
Mid term     
Targets 6-month :  0.55 1-year :  0.6
Resists First :  0.47 Second :  0.51
Pivot price 0.47
Supports First :  0.42 Second :  0.35
MAs MA(5) :  0.44 MA(20) :  0.47
MA(100) :  0.78 MA(250) :  2.51
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  22.7 D(3) :  20.4
RSI RSI(14): 33.2
52-week High :  6.44 Low :  0.42
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ BIVI ] has closed above bottom band by 7.4%. Bollinger Bands are 75.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 47 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.45 - 0.45 0.45 - 0.46
Low: 0.42 - 0.42 0.42 - 0.43
Close: 0.43 - 0.44 0.44 - 0.45
Company Description

BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.

Headline News

Sun, 26 May 2024
Moving Average Crossover Alert: BioVie (BIVI) - Yahoo Lifestyle UK

Tue, 26 Mar 2024
Lawsuit Notice: Investors who lost money with BioVie Inc. (NASDAQ: BIVI) shares should contact the Shareholders ... - PR Newswire

Wed, 13 Mar 2024
BIVI Investors Have Opportunity to Lead BioVie Inc. Securities Fraud Lawsuit - PR Newswire

Tue, 12 Mar 2024
Bears are Losing Control Over BioVie Inc. (BIVI), Here's Why It's a 'Buy' Now - Yahoo Finance

Sun, 10 Mar 2024
SHAREHOLDER ALERT: Potential Recovery for BioVie Inc. (BIVI) Investors - TipRanks.com - TipRanks

Wed, 06 Mar 2024
BioVie Inc. Announces Closing of Public Offering - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 55 (M)
Shares Float 23 (M)
Held by Insiders 43.2 (%)
Held by Institutions 6 (%)
Shares Short 1,270 (K)
Shares Short P.Month 1,480 (K)
Stock Financials
EPS -1.17
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.18
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -80.9 %
Return on Equity (ttm) -257.9 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.81
Qtrly Earnings Growth 0 %
Operating Cash Flow -41 (M)
Levered Free Cash Flow -30 (M)
Stock Valuations
PE Ratio -0.38
PEG Ratio 0
Price to Book value 2.31
Price to Sales 0
Price to Cash Flow -0.59
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android